Citations

Showing 10 of 108083 citations.

Seasonal variation in blood pressure control across US health systems
Nilles, Ester Kim , Champon, XiaoXia, Mulder, Hillary, Shaw, Kathryn M., Smith, Myra, Lampron, Zachary, Viera, Anthony J. , Chuang, Cynthia H. , McTigue, Kathleen M. , McClay, James C. , Maeztu, Carlos , Sanders, Margaret , Warren, Nate, VanWormer, Jeffrey J. , Modrow, Madelaine Faulkner , Pletcher, Mark J. , O’Brien, Emily C. , Mulder, Hillary , Pletcher, Mark J , Mulder, Hillary , Faulkner Modrow, Madelaine , Wozniak, Gregory , Chamberlain, Alanna M. , Carton, Thomas W. , Ahmad, Faraz S. , Steinberg, Benjamin A. , Polonsky, Tamar S. , Singh, Rajbir , Liu, Mei , Park, Soohyung , Rakotz, Michael , Cooper‐DeHoff, Rhonda M.

Mayo Clinic

Journal of Hypertension | March 8, 2023 | Volume: 41 | Issue: 5 | Pages: 751-758

10.1097/hjh.0000000000003396 | PMID 36883471 Get It

Objective: We aimed to characterize seasonal variation in US population-based blood pressure (BP) control and BP-related metrics and evaluate the association between outdoor temperature and BP control variation. Methods: We queried electronic health records (EHRs) from 26 health systems, representing 21 states, to summarize BP metrics by quarters of 12-month periods from January 2017 to March 2020. Patients with at least one ambulatory visit during the measurement period and a hypertension diagnosis during the first 6 months or prior to the measurement period were included. Changes in BP control, BP improvement, medication intensification, average SBP reduction after medication intensification across quarters and association with outdoor temperature were analyzed using weighted generalized linear models with repeated measures. Results: Among 1 818 041 people with hypertension, the majority were more than 65 years of age (52.2%), female (52.1%), white non-Hispanic (69.8%) and had stage 1/2 hypertension (64.8%). Overall, BP control and process metrics were highest in quarters 2 and 3, and lowest in quarters 1 and 4. Quarter 2 had the highest percentage of improved BP (31.95 ± 0.90%) and average SBP reduction after medication intensification (16 ± 0.23 mmHg). Quarter 3 had the highest percentage of BP controlled (62.25 ± 2.55%) and lowest with medication intensification (9.73 ± 0.60%). Results were largely consistent in adjusted models. Average temperature was associated with BP control metrics in unadjusted models, but associations were attenuated following adjustment. Conclusion: In this large, national, EHR-based study, BP control and BP-related process metrics improved during spring/summer months, but outdoor temperature was not associated with performance following adjustment for potential confounders.
Mechanical Thrombectomy Global Access For Stroke (MT-GLASS): A Mission Thrombectomy (MT-2020 Plus) Study
Asif, Kaiz , Otite, Fadar Oliver , Desai, Shashvat M. , Herial, Nabeel , Inoa, Violiza , Al‐Mufti, Fawaz , Dmytriw, Adam A. , Castonguay, Alicia C. , Khandelwal, Priyank , Potter‐Vig, Jennifer , Szeder, Viktor , Kulman, Tanzila, Masoud, Hesham , Tóth, Gábor , Limaye, Kaustubh , Aroor, Sushanth , Brinjikji, Waleed , Rai, Ansaar , Gebreyohanns, Mehari , Leung, Thomas , Mansour, Malek , Huded, Vikram , Zaidat, Osama O. , Sylaja, PN , Yavagal, Dileep R. , Cirio, Juan , Lylyk, Pedro , Ferrario, Ángel, Plaghos, Luis Lemme, Ibrahim, Wael Hamed, Alnidawi, Firas , Islam, Sirajee Shafiqul, Shahidullah, Mohammad, Saavedra, Víctor Villarroel, Alverne, Francisco Josà Mont’, Magalhães, Pedro , Sirakov, Stanimir , Kalpachki, Rosen, Alioski, Nurfet, Lamou, Eric Gueumekane Bila , Rowe, Daidre, Gayle, Francene , Souza, Romnesh de, Ramos, Cristina , GarcÃa, Amaury, Ali, Amza , Sandy, Sherry , Guzman, Tony Fabian Alvarez, Villarraga, Alejandro, Estrada, Carolina, Pabón, B , Adebayo, Philip , ABDO, GERMAN, S, Nelson Maldonado, Khinikadze, Mirza, Tsiskaridze, Alexander , Syrmos, Νikolaos , Mitsias, Panayiotis , Das, Biplab , Gupta, Vipul , Karapurkar, Anil, Stivastava, M.V.Padma, Alurkar, Anand, Sharma, Arvind , Lahoti, Satish, Kuruttukulam, Gigy , Sari, Ita Muharram , Khassaf, Mustafa Saleem, Nassir, Temeem Majid, Yamagami, Hiroshi , Dababneh, Haitham, Aladham, Farid A., Berdikhojayev, Mynzhylky , Medukhanova, Sabina , Kikano, Raghid, Alaraj, Ali , Ahdab, Rechdi , Zaidi, Wan Asyraf Wan , Kadir, Khairul Azmi Abd, Gongora, Fernando, Jambaldorj, Ariunaa , XXX, Ganbaatar, Shwe, Zarni Myint, Thit, Win Min , RAYO, ERWIN E., Makanjuola, Akintomiwa , Rashid, Umair, Mernes, Ricardo, Paniagua, Osvaldo, GALLO, MARLA, Moquillaza, Manuel, Collantes, Maria Epifania , Mariano, Manuel, Kobayashi, Adam , Rodríguez‐Mercado, Rafael, Guardia, Rodolfo Alcedo, Imam, Yahia , Ahmed, Ayman Z., Al-Jehani, Hosam , Lee, Wickly, Klepanec, Andrej , Brey, Naeem , Rossouw, Anastasia, Silva, Prasad De, Gunasekera, Harsha, Ranawaka, Udaya K. , Osman, Haytham , El-Sadig, Sarah , Suwanwela, Nijasri C., Akarathanawat, Wasan, Tantivatana, Jarturon , Hammami, Nadia, Giray, Semih , Lebedynets, Dmytro , Konotopchik, Stanislav, John, Seby , Hussain, Syed , Novakovic-White, Robin, Perue, Gillian L Gordon, Then, Ryna , Berrutti, Claudio, Crosa, Roberto , Nguyen, Huy Thang, Le, Huynh Vu, vu, Tran thanh, Asif, Kaiz S , Otite, Fadar O , Jadhav, Ashutosh P , Dmytriw, Adam A , Castonguay, Alicia , Khandelwal, Priyank , Szeder, Viktor , Urrutia, Victor C , Masoud, Hesham , Toth, Gabor , Limaye, Kaustubh , Brinjikji, Waleed , Rai, Ansaar , Pandian, Jeyaraj , Leung, Thomas , Mansour, Ossama , Demchuk, Andrew M , Martins, Sheila , Zaidat, Osama O , Huo, Xiaochuan , Campbell, Bruce , Miao, Zhongrong , Saver, Jeffrey , Ortega-Gutierrez, Santiago , Yavagal, Dileep R , Crosa, Roberto , Alaraj, Ali , Al-Mufti, Fawaz , Jadhav, Ashutosh P. , Urrutia, Victor , Pandian, Jeyaraj , Demchuk, Andrew M. , Saver, Jeffrey L. , Arroyo, José, Yan, Bernard , Chandra, Ronil Vikesh , Shahidullah, Mohammad, Alverne, F Mont, Silva, Gisele Sampaio , Shankar, Jai , Stotts, Grant , Ramos, Cristina, Lavados, Pablo M. , Rivera, Rodrigo , Krajina, Antonı́n , Tomek, Aleš , Hassan, Farouk , Khedr, Eman M. , Nadareishvili, Zurab , Roy, Jayanta , Gupta, Vivek , Khurana, Dheeraj , Kumar, Rahul Kewal , Sani, Achmad Firdaus , Sakai, Nobuyuki , Aladham, Farid, Kikano, Raghid , Araúz, Antonio , Góngora‐Rivera, Fernando , Shwe, Zarni Myint, Ranta, Annemarei , Wu, Teddy Y , Owolabi, Mayowa , Ahmad, Saima , Wasay, Mohammad , Alhazzani, Adel Ali , Zeleňák, Kamil , Krastev, Georgi , Frol, Senta , Hammami, Nadia, Sassi, Samia Ben , Özdemi̇r, Atilla Özcan , Конотопчик, С. В., Perue, Gillian Gordon

Mayo Clinic

Circulation | March 8, 2023 | Volume: 147 | Issue: 16 | Pages: 1208-1220

10.1161/circulationaha.122.063366 | PMID 36883458 Get It

Background: Despite the well-established potent benefit of mechanical thrombectomy (MT) for large vessel occlusion (LVO) stroke, access to MT has not been studied globally. We conducted a worldwide survey of countries on 6 continents to define MT access (MTA), the disparities in MTA, and its determinants on a global scale. Methods: Our survey was conducted in 75 countries through the Mission Thrombectomy 2020+ global network between November 22, 2020, and February 28, 2021. The primary end points were the current annual MTA, MT operator availability, and MT center availability. MTA was defined as the estimated proportion of patients with LVO receiving MT in a given region annually. The availability metrics were defined as ([current MT operators×50/current annual number of estimated thrombectomy-eligible LVOs]×100 = MT operator availability) and ([current MT centers×150/current annual number of estimated thrombectomy-eligible LVOs]×100= MT center availability). The metrics used optimal MT volume per operator as 50 and an optimal MT volume per center as 150. Multivariable-adjusted generalized linear models were used to evaluate factors associated with MTA. Results: We received 887 responses from 67 countries. The median global MTA was 2.79% (interquartile range, 0.70–11.74). MTA was <1.0% for 18 (27%) countries and 0 for 7 (10%) countries. There was a 460-fold disparity between the highest and lowest nonzero MTA regions and low-income countries had 88% lower MTA compared with high-income countries. The global MT operator availability was 16.5% of optimal and the MT center availability was 20.8% of optimal. On multivariable regression, country income level (low or lower–middle versus high: odds ratio, 0.08 [95% CI, 0.04–0.12]), MT operator availability (odds ratio, 3.35 [95% CI, 2.07–5.42]), MT center availability (odds ratio, 2.86 [95% CI, 1.84–4.48]), and presence of prehospital acute stroke bypass protocol (odds ratio, 4.00 [95% CI, 1.70–9.42]) were significantly associated with increased odds of MTA. Conclusions: Access to MT on a global level is extremely low, with enormous disparities between countries by income level. The significant determinants of MT access are the country’s per capita gross national income, prehospital LVO triage policy, and MT operator and center availability.
Pragmatic, Prospective Comparative Effectiveness Trial of Carbon Ion Therapy, Surgery, and Proton Therapy for the Management of Pelvic Sarcomas (Soft Tissue/Bone) Involving the Bone: The PROSPER Study Rationale and Design
Petersen, Ivy A. , Imai, Reiko , Hug, Eugen B., Fiore, Maria Rosaria , Fossati, Piero , Yamada, Shigeru , Orlandi, Ester , Zhang, Qing, Bao, Cihang , Seidensaal, Katharina , May, Byron C. , Harrell, Anna , Houdek, Matthew T. , Vallow, Laura A., Rose, Peter S. , Haddock, Michael G. , Ashman, Jonathan B. , Goulding, Krista , Attia, Steven , Krishnan, Sunil , Mahajan, Anita , Foote, Robert L. , Keole, Sameer R., Beltran, Chris , Welch, Eric M., Wilke, Benjamin K. , Imai, Reiko , Yamada, Shigeru , Zhang, Qing , May, Byron C , Harrell, Anna C , Houdek, Matthew T , Goulding, Krista A., Krishnan, Sunil , Foote, Robert , Karim, Mohammed, Ahmed, Safia K. , Beltran, Chris J , Hoppe, Bradford S. , DeWees, T.A. , Debus, Jürgen , Laack, Nadia N. , Karim, Mohammed

Mayo Clinic

Cancers | March 8, 2023 | Volume: 15 | Issue: 6 | Pages: 1660

10.3390/cancers15061660 | PMID 36980545 Get It

Surgical treatment of pelvic sarcoma involving the bone is the standard of care but is associated with several sequelae and reduced functional quality of life (QOL). Treatment with photon and proton radiotherapy is associated with relapse. Carbon ion radiotherapy (CIRT) may reduce both relapse rates and treatment sequelae. The PROSPER study is a tricontinental, nonrandomized, prospective, three-arm, pragmatic trial evaluating treatments of pelvic sarcoma involving the bone. Patients aged at least 15 years are eligible for inclusion. Participants must have an Eastern Cooperative Oncology Group Performance Status score of two or less, newly diagnosed disease, and histopathologic confirmation of pelvic chordoma, chondrosarcoma, osteosarcoma, Ewing sarcoma with bone involvement, rhabdomyosarcoma (RMS) with bone involvement, or non-RMS soft tissue sarcoma with bone involvement. Treatment arms include (1) CIRT (n = 30) delivered in Europe and Asia, (2) surgical treatment with or without adjuvant radiotherapy (n = 30), and (3) proton therapy (n = 30). Arms two and three will be conducted at Mayo Clinic campuses in Arizona, Florida, and Minnesota. The primary end point is to compare the 1-year change in functional QOL between CIRT and surgical treatment. Additional comparisons among the three arms will be made between treatment sequelae, local control, and other QOL measures.
Traumatic posterior cerebral artery dissection and dissecting aneurysms: A systematic review with an illustrative case report
Essibayi, Muhammed Amir , Kerezoudis, Panagiotis, Keser, Zafer , Essibayi, Muhammed Amir , Kerezoudis, Panagiotis , Keser, Zafer , Lanzino, Giuseppe

Mayo Clinic

Interventional Neuroradiology | March 8, 2023 | Volume: 32 | Issue: 3 | Pages: 691-697

10.1177/15910199231162487 | PMID 36883231 Get It

Background Traumatic posterior cerebral artery (tPCA) dissection and dissecting aneurysms are rare and constitute a challenging clinical entity. Objective We analyze existing literature on tPCA dissection and present our institutional experience. Methods We retrospectively queried our database for tPCA isolated dissection or dissecting aneurysms from 2008 until now and conducted a systematic literature review of published cases. We analyzed the clinical and radiographic characteristics and treatment outcomes of tPCA dissection. Results Including our case, a total of 11 cases with either isolated dissection ( n = 2) or dissecting aneurysms ( n = 9) were included. The median age was 27 years, and 45% were females. The median interval between trauma and tPCA dissection diagnosis was nine days. Mental status declined in four (36%) patients. Half of the patients demonstrated tentorial subdural hematoma on head CT. Ischemic stroke was detected in three (43%) patients. Four (36%) patients were conservatively managed, one (9.1%) patient was treated with surgical clipping of the proximal PCA, and six patients underwent endovascular treatments. The complication rate was 20%. Immediate total occlusion was demonstrated in five patients (100%), and the conservatively managed case showed immediate, spontaneous thrombosis of the aneurysm. Glasgow Coma Scale scores were 15 in eight (89%) and 14 in one (11%) patients at the last clinical follow-up with a median of six months. The mortality and retreatment rates were null. Conclusions tPCA dissection is diagnosed late and commonly affects the young population. The clinical outcome for this condition is typically favorable. Current endovascular techniques showed considerable efficacy and safety.
In Silico Binding of 2-Aminocyclobutanones to SARS-CoV-2 Nsp13 Helicase and Demonstration of Antiviral Activity
Mohammad, Thahani S. Habeeb , Gupta, Yash , Reidl, Cory T. , Nicolaescu, Vlad , Gula, Haley , Durvasula, Ravi , Kempaiah, Prakasha , Becker, Daniel P. , Kempaiah, Prakasha , Becker, Daniel P , Gupta, Yash

Mayo Clinic

International Journal of Molecular Sciences | March 8, 2023 | Volume: 24 | Issue: 6 | Pages: 5120

10.3390/ijms24065120 | PMID 36982188 Get It

The landscape of viral strains and lineages of SARS-CoV-2 keeps changing and is currently dominated by Delta and Omicron variants. Members of the latest Omicron variants, including BA.1, are showing a high level of immune evasion, and Omicron has become a prominent variant circulating globally. In our search for versatile medicinal chemistry scaffolds, we prepared a library of substituted ɑ-aminocyclobutanones from an ɑ-aminocyclobutanone synthon (11). We performed an in silico screen of this actual chemical library as well as other virtual 2-aminocyclobutanone analogs against seven SARS-CoV-2 nonstructural proteins to identify potential drug leads against SARS-CoV-2, and more broadly against coronavirus antiviral targets. Several of these analogs were initially identified as in silico hits against SARS-CoV-2 nonstructural protein 13 (Nsp13) helicase through molecular docking and dynamics simulations. Antiviral activity of the original hits as well as ɑ-aminocyclobutanone analogs that were predicted to bind more tightly to SARS-CoV-2 Nsp13 helicase are reported. We now report cyclobutanone derivatives that exhibit anti-SARS-CoV-2 activity. Furthermore, the Nsp13 helicase enzyme has been the target of relatively few target-based drug discovery efforts, in part due to a very late release of a high-resolution structure accompanied by a limited understanding of its protein biochemistry. In general, antiviral agents initially efficacious against wild-type SARS-CoV-2 strains have lower activities against variants due to heavy viral loads and greater turnover rates, but the inhibitors we are reporting have higher activities against the later variants than the wild-type (10–20X). We speculate this could be due to Nsp13 helicase being a critical bottleneck in faster replication rates of the new variants, so targeting this enzyme affects these variants to an even greater extent. This work calls attention to cyclobutanones as a useful medicinal chemistry scaffold, and the need for additional focus on the discovery of Nsp13 helicase inhibitors to combat the aggressive and immune-evading variants of concern (VOCs).
A nationwide study of liver disease hospitalizations during the coronavirus pandemic in the United States
Sedarous, Mary , Youssef, Michael , Adekunle, Ayooluwatomiwa D. , Babajide, Oyedotun , Mahmud, Muftah, Rubens, Muni , Okafor, Philip N. , Sedarous, Mary , Youssef, Michael

Mayo Clinic

Journal of Gastroenterology and Hepatology | March 8, 2023 | Volume: 38 | Issue: 7 | Pages: 1148-1157

10.1111/jgh.16170 | PMID 36882309 Get It

AbstractBackground and AimThe impact of the Coronavirus disease‐2019 (COVID‐19) pandemic on patients with liver disease is not well described at the population level in the United States. We used the largest, nationwide inpatient dataset to describe inpatient liver disease outcomes in the United States during the first year of the pandemic (2020) using 2018 and 2019 as comparator years.MethodsUsing the National Inpatient Sample (2018–2020), we explored year‐to‐year and 2020 month‐to‐month trends in hospitalizations, length of stay, and inpatient mortality for liver‐related complications including cirrhosis, alcohol‐associated liver disease (ALD) and alcoholic hepatitis using regression modeling. We reported relative change (RC) in the study period.ResultsDecompensated cirrhosis hospitalizations decreased in 2020 compared with 2019 (RC: −2.7%, P < 0.001) while all‐cause mortality increased by 15.5% (P < 0.001). Hospitalizations for ALD increased compared with pre‐pandemic years (RC: 9.2%, P < 0.001) with a corresponding increase in mortality in 2020 (RC 25.2%, P = 0.002). We observed an increase in liver transplant surgery mortality during the peak months of the pandemic. Importantly, mortality from COVID‐19 was higher among patients with decompensated cirrhosis (adjusted odds ratio [OR] 1.72, 95% confidence interval [CI] [1.53–1.94]), Native Americans (OR 1.76, 95% CI [1.53–2.02]), and patients from lower socioeconomic groups.ConclusionsCirrhosis hospitalizations decreased in 2020 compared with pre‐pandemic years but were associated with higher all‐cause mortality rates particularly in the peak months of the COVID‐19 pandemic. In‐hospital COVID‐19 mortality was higher among Native Americans, patients with decompensated cirrhosis, chronic illnesses, and those from lower socioeconomic groups.
Targeting Fibroblast Growth Factor Receptor Pathway: Precision Medicine for Biliary Cancer and Beyond
Usón, Pedro Luiz Serrano , Uson Junior, Pedro Luiz Serrano, Uson, Pedro L S , Borad, Mitesh J.

Mayo Clinic

Seminars in Liver Disease | March 8, 2023 | Volume: 43 | Issue: 02 | Pages: 218-225

10.1055/a-2049-3149 | PMID 36882151 Get It

Fibroblast growth factor receptor 2 (FGFR2) inhibitors are now being included in the treatment guidelines of multiple countries for patients with advanced cholangiocarcinoma (CCA). Activation of the FGF–FGFR pathway is related to proliferation and tumor progression. Targeting the FGF–FGFR pathway is effective and can yield durable responses in patients with CCA harboring FGFR2 fusions or rearrangements. In this review article, we address molecules and clinical trials evaluating FGFR inhibitors in advanced CCA. We will further discuss identified mechanisms of resistance and the strategies to overcome it. The incorporation of next-generation sequencing in advanced CCA and circulating tumor DNA on disease progression will unveil mechanisms of resistance and improve the development of future clinical trials and more selective drugs and combinations.
Clinical Characteristics and Treatment Patterns of Open Hand Fractures in the Pediatric Population
Parrado, Raphael H. , Foster, Lukas , Gilbert, Megan , Movtchan, Nellie V., Sayrs, Lois W. , Khoury, Emily, Ballan, Wassim , Schaub, Timothy A., Movtchan, Nellie

Mayo Clinic

Journal of Pediatric Orthopaedics | March 8, 2023 | Volume: 43 | Issue: 5 | Pages: e358-e362

10.1097/bpo.0000000000002379 | PMID 36882896 Get It

Background: Open hand fractures are one of the most common injuries in the pediatric population. These injuries are at higher risk of infection, especially in cases of frank contamination. Several studies on adult hand fractures are available in the literature; however, pediatric open hand fractures have yet to be extensively studied. This study aimed to define pediatric open hand fracture’s demographics, clinical characteristics, and treatment patterns. Methods: Using the Protected Health Information database, pediatric patients (<18 y old) with the diagnosis of open hand fracture from June 2016 to June 2018 were extracted. Demographic, treatment, and follow-up data were collected. Clinical outcomes included readmission and postoperative infection rates. Results: There were a total of 4516 patients who met the inclusion criteria; the median age was 7 years (interquartile range: 3 to 11); 60% males; 60% white. Displaced fractures occurred in 74% of patients, with the right hand (52%) and middle finger (27%) predominance. The most common mechanism of injury was a crushing injury in-between objects (56%). Associated nerve injury occurred in 78 patients (4%) and vascular injury in 43 patients (2%). Open reduction and internal fixation were performed in 30% of patients. Cephalosporins were the most commonly prescribed antibiotics (73%), followed by aminopenicillins (7%). Nine patients had complications related to surgical intervention (0.2%), and postoperative infection occurred in 44 patients (1%). Conclusions: Pediatric open hand fractures most often occur during childhood and more frequently in males. These fractures tend to be more distal and displaced; reduction and fixation are required in one-third of the cases. Despite the absence of treatment guidelines and variability, this injury exhibits low complication rates. Level of Evidence: Level III, retrospective study.
A268 RESOLUTION RATES IN OPEN-LABEL VERSUS RANDOMIZED CONTROLLED TRIALS FOR MICROBIOTA RESTORATION FOR RECURRENT CLOSTRIDIOIDES DIFFICILE INFECTION: AN UPDATED META-ANALYSIS
Pardi, Darrell S. , Khanna, Sahil , Tariq, Raseen

Mayo Clinic

Journal of the Canadian Association of Gastroenterology | March 7, 2023 | Volume: 6 | Issue: Supplement_1 | Pages: 85-85

10.1093/jcag/gwac036.268 Get It

Abstract Background Microbiota restoration is highly effective to treat recurrent Clostridioides difficile infection (CDI) in observational studies (cure rates &gt;90%) but efficacy in controlled clinical trials appears lower. Purpose We performed an updated meta-analysis to assess the efficacy of microbiota restoration for recurrent CDI in open-label registered prospective clinical trials compared to randomized controlled trials (RCTs). Method A systematic search of Embase, Web of Science and Scopus was performed up to June 2022 to identify studies of interest. Clinical trials of microbiota restoration for recurrent CDI with clinical resolution with one dose as the primary outcome were included. We calculated both unweighted and weighted pooled resolution rates (UPR and WPR) with 95% confidence intervals (CI). Result(s) Eighteen studies (9 RCTs and 9 open-label trials) with 1149 CDI patients were included. Of the patients treated with microbiota restoration, 881 experienced symptom resolution (UPR 77%%; WPR 79%, 95% CI, 72%-85%). There was significant heterogeneity among studies with an I2of 86%. Analysis of trials with a control arm (non-microbiota restoration) revealed CDI resolution in 357 of 496 patients (UPR 72%; WPR 73%, 95% CI 63%-82%) with microbiota restoration. Among the 9 open-label clinical trials, CDI resolution was seen in 524 of 653 patients after initial microbiota restoration (UPR 80%; WPR 84%, 95% CI 74%-92%). Comparison of resolution rates between RCTs and open-label trials revealed a lower cure rate in RCTs compared to open-label trials (WPR 73% vs 84%, p&lt;0.0001). Analysis of the 10 trials with non-microbiota restoration revealed CDI resolution in 201 of 397 patients with antibiotics (WPR 52%, 95% CI 43%-60%). There was significant heterogeneity among the included studies with an I2of 61%. Comparison of cure rates with microbiota restoration vs antibiotics showed higher cure rate with microbiota restoration (WPR 73%, [95% CI 63%-82%] vs 52% [95% CI, 43%-60%]; p&lt;0.0001). There were no serious adverse events reported. Conclusion(s) Microbiota restoration in a randomized controlled setting leads to lower resolution rates compared to open label and observational settings, likely due to stricter definitions and inclusion criteria. Resolution rates in open label studies were similar to observational studies. Please acknowledge all funding agencies by checking the applicable boxes below None Disclosure of Interest None Declared
A233 OUTCOMES OF CLOSTRIDIOIDES DIFFICILE INFECTION IN SURGICAL PATIENTS: RESULTS FROM NATIONAL INPATIENT SAMPLE 2016-2019
Tahir, Muhammad Waqas , Khanna, Sahil , Tariq, Raseen

Mayo Clinic

Journal of the Canadian Association of Gastroenterology | March 7, 2023 | Volume: 6 | Issue: Supplement_1 | Pages: 64-65

10.1093/jcag/gwac036.233 Get It

Abstract Background Clostridioides difficile infection (CDI) is the most common nosocomial infection and is associated with significant morbidity and mortality. Purpose We aimed to identify the burden of CDI in patients undergoing common gastrointestinal (GI) surgical procedures in a national inpatient cohort, as GI surgeries have been thought to be a risk factor for CDI. Method We used the National Inpatient Sample (NIS) database from Unites States for the years 2016-2019 for this study. We included adult patients (age ≥ 18), who underwent common GI surgeries (identified using ICD-10 procedure codes), and among them identified patients with diagnosis of CDI. Outcomes assessed included risk of CDI among different surgeries, inpatient mortality, length of stay (LOS) and cost of hospitalization using regression analyses Result(s) From 2016 to 2019, an estimated total of 4,438,778 patients were hospitalized and underwent any of the studied GI surgeries. CDI was reported in 32,180 admissions (0.72%). Median age for CDI was higher than non-CDI patients (66 vs 56, p&lt;0.001). Incidence of CDI was 2.5 times higher in patients admitted emergently compared to elective admissions (1.00% vs 0.40%, p&lt;0.0001). Among all surgeries, the incidence of CDI was the highest for small bowel resection at 2.1% followed by partial esophagectomy at 1.6% and partial colectomy at 1.4%. Logistic regression analysis showed the patients undergoing esophagectomy had the highest risk with adjusted Odds Ratio (aOR) of 2.48, (95% CI 2.01 – 3.07, p&lt;0.0001), followed by pancreatectomy with aOR 2.03 (95% CI 1.91 – 2.16, p&lt;0.0001). Overall, surgical patients with CDI had a significantly higher in-patient mortality compared to non-CDI patients (8.2% vs 1.4%, p&lt;0.0001). Logistic regression analysis showed an increased risk of inpatient mortality with CDI, with aOR 1.36, 95% CI 1.30 – 1.42, p&lt;0.0001. Median LOS for surgical patients with CDI was higher than non-CDI patients (14 days vs 3 days, p&lt;0.0001). The linear regression analysis for length of stay showed that among patients undergoing surgical procedures, CDI was associated with an increased LOS with beta of 8.39 days ± SE 0.04 (95% CI 8.31 – 8.46, p&lt;0.0001). The mean cost of hospitalization for surgical patients with CDI was higher than non-CDI patients ($90,590 vs $31,702, p&lt;0.0001) after adjusting for inflation over the four-year period. The linear regression analysis showed that CDI was associated with an increased cost of hospitalization with a beta of $25,343 ± SE 166 (95% CI 25,017 – 25,670, p&lt;0.0001). Conclusion(s) CDI among GI surgeries leads to increase in inpatient mortality, length of stay and cost of hospitalization. Although the rate of CDI is showing a downwards trend, its impact on these outcome measures makes it an important complication to prevent and promptly treat in these surgical patients. Please acknowledge all funding agencies by checking the applicable boxes below None Disclosure of Interest None Declared